JO3067B1 - بيرميدينات بيرازولو امينو كمثبطات ل fak - Google Patents

بيرميدينات بيرازولو امينو كمثبطات ل fak

Info

Publication number
JO3067B1
JO3067B1 JOP/2009/0395A JOP20090395A JO3067B1 JO 3067 B1 JO3067 B1 JO 3067B1 JO P20090395 A JOP20090395 A JO P20090395A JO 3067 B1 JO3067 B1 JO 3067B1
Authority
JO
Jordan
Prior art keywords
pyrazolylaminopyridines
fak
inhibitors
present
cancers
Prior art date
Application number
JOP/2009/0395A
Other languages
English (en)
Inventor
H Faitg Thomas
Leroy Adams Jerry
W Johnson Neil
Lin Hong
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3067(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of JO3067B1 publication Critical patent/JO3067B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Abstract

يتعلق الاختراع الحالي لمركب الصياغة(I): (I) أو ملح مقبول صيدلانيا لهم, حيث R1, R2, R3, R11, R12, R13, Q, Z وp هم كما وصف هنا. مركبات الاختراع الحالي تكون مفيدة لعلاج السرطانات.
JOP/2009/0395A 2008-10-27 2009-10-25 بيرميدينات بيرازولو امينو كمثبطات ل fak JO3067B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
JO3067B1 true JO3067B1 (ar) 2017-03-15

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0395A JO3067B1 (ar) 2008-10-27 2009-10-25 بيرميدينات بيرازولو امينو كمثبطات ل fak

Country Status (36)

Country Link
US (6) US20110207743A1 (ar)
EP (1) EP2421537B1 (ar)
JP (1) JP5642689B2 (ar)
KR (1) KR101512217B1 (ar)
CN (1) CN102264371B (ar)
AR (1) AR073993A1 (ar)
AU (1) AU2009320144B2 (ar)
BR (1) BRPI0920053B8 (ar)
CA (1) CA2741760C (ar)
CL (1) CL2011000933A1 (ar)
CO (1) CO6361929A2 (ar)
CR (1) CR20110264A (ar)
CY (1) CY1116399T1 (ar)
DK (1) DK2421537T3 (ar)
DO (1) DOP2011000113A (ar)
EA (1) EA021927B1 (ar)
ES (1) ES2539835T3 (ar)
HK (1) HK1161680A1 (ar)
HR (1) HRP20150531T1 (ar)
IL (1) IL212444A (ar)
JO (1) JO3067B1 (ar)
MA (1) MA32727B1 (ar)
MX (1) MX2011004369A (ar)
MY (1) MY161890A (ar)
NZ (1) NZ592477A (ar)
PE (1) PE20110941A1 (ar)
PL (1) PL2421537T3 (ar)
PT (1) PT2421537E (ar)
RS (1) RS54045B1 (ar)
SG (1) SG195608A1 (ar)
SI (1) SI2421537T1 (ar)
SM (1) SMT201500157B (ar)
TW (1) TWI454467B (ar)
UY (1) UY32200A (ar)
WO (1) WO2010062578A1 (ar)
ZA (1) ZA201102892B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
CN103476413B (zh) * 2011-01-26 2016-03-16 葛兰素史密斯克莱知识产权有限公司 组合
JP5937112B2 (ja) 2011-02-17 2016-06-22 カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ 選択的ｆａｋ阻害剤
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2013003575A1 (en) * 2011-06-28 2013-01-03 Glaxosmithkline Llc Method of administration and treatment
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
CN108289892B (zh) 2015-06-29 2021-11-23 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
US20220040317A1 (en) * 2018-09-27 2022-02-10 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
WO2000014105A1 (en) * 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
BR122019017579B8 (pt) * 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
EP2727909A1 (en) * 2007-03-16 2014-05-07 The Scripps Research Institute Inhibitors of focal adhesion kinase
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
MX2010014057A (es) * 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.

Also Published As

Publication number Publication date
AU2009320144A1 (en) 2010-06-03
RS54045B1 (en) 2015-10-30
PE20110941A1 (es) 2012-02-08
HRP20150531T1 (hr) 2015-06-19
JP5642689B2 (ja) 2014-12-17
TW201028394A (en) 2010-08-01
KR20110080172A (ko) 2011-07-12
US20160095841A1 (en) 2016-04-07
AR073993A1 (es) 2010-12-15
EP2421537A1 (en) 2012-02-29
IL212444A0 (en) 2011-06-30
MY161890A (en) 2017-05-15
CA2741760C (en) 2016-02-23
CN102264371B (zh) 2013-10-02
CO6361929A2 (es) 2012-01-20
CY1116399T1 (el) 2017-02-08
PT2421537E (pt) 2015-07-03
MX2011004369A (es) 2011-05-25
EA021927B1 (ru) 2015-09-30
IL212444A (en) 2015-11-30
BRPI0920053B8 (pt) 2021-05-25
UY32200A (es) 2010-05-31
KR101512217B1 (ko) 2015-04-15
EP2421537B1 (en) 2015-04-08
JP2012506876A (ja) 2012-03-22
SI2421537T1 (sl) 2015-06-30
EA201170617A1 (ru) 2011-12-30
CA2741760A1 (en) 2010-06-03
ZA201102892B (en) 2012-02-29
CL2011000933A1 (es) 2011-10-21
US20150265589A1 (en) 2015-09-24
WO2010062578A1 (en) 2010-06-03
US20110269774A1 (en) 2011-11-03
US20100113475A1 (en) 2010-05-06
US9012479B2 (en) 2015-04-21
BRPI0920053B1 (pt) 2019-11-26
EP2421537A4 (en) 2012-06-13
TWI454467B (zh) 2014-10-01
AU2009320144B2 (en) 2013-11-21
DK2421537T3 (da) 2015-06-22
SG195608A1 (en) 2013-12-30
BRPI0920053A2 (pt) 2015-12-15
US20110207743A1 (en) 2011-08-25
CN102264371A (zh) 2011-11-30
US9446034B2 (en) 2016-09-20
DOP2011000113A (es) 2011-07-15
MA32727B1 (ar) 2011-10-02
CR20110264A (es) 2011-10-04
HK1161680A1 (en) 2012-08-03
ES2539835T3 (es) 2015-07-06
NZ592477A (en) 2013-01-25
US20140107131A1 (en) 2014-04-17
SMT201500157B (it) 2015-09-07
PL2421537T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2012008874A (es) Macrociclos como inhibidores del factor de coagulacion (fxia).
TN2011000400A1 (en) Inhibitors of beta-secretase
MY158982A (en) Heterocyclic compound
MX2009000884A (es) Derivados de piridizinona.
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
EA201290632A1 (ru) Производные бетулина
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
TN2012000401A1 (en) Heterocyclic compound
MY184008A (en) Aryl pyridine as aldosterone synthase inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
SG171593A1 (en) Inhibitors of c-fms kinase
TN2012000248A1 (en) Novel spiropiperidine compounds
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MY150778A (en) Fused heterocyclic compound
EA201190293A1 (ru) Пролекарства триптолида
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
EA201270302A1 (ru) Безводные формы производных пиридина
IL207250A0 (en) Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas